"sitaxsentan"[nm] - Search Results

Year	Number of Results
1997	1
1998	2
1999	1
2000	1
2001	5
2002	3
2003	5
2004	8
2005	7
2006	10
2007	15
2008	15
2009	17
2010	15
2011	15
2012	18
2013	10
2014	6
2015	3
2016	2
2017	2
2018	1
2019	3
2020	3
2024	0

1

Sitaxsentan for treatment of pulmonary hypertension.

Wittbrodt ET, Abubakar A. Wittbrodt ET, et al. Ann Pharmacother. 2007 Jan;41(1):100-5. doi: 10.1345/aph.1G254. Epub 2006 Dec 12. Ann Pharmacother. 2007. PMID: 17164394 Review.

2

Sitaxsentan in the management of pulmonary arterial hypertension.

Benedict NJ. Benedict NJ. Am J Health Syst Pharm. 2007 Feb 15;64(4):363-8. doi: 10.2146/ajhp060357. Am J Health Syst Pharm. 2007. PMID: 17299175 Review.

3

Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.

Barst RJ. Barst RJ. Expert Opin Pharmacother. 2007 Jan;8(1):95-109. doi: 10.1517/14656566.8.1.95. Expert Opin Pharmacother. 2007. PMID: 17163810 Review.

4

Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension.

Sandoval J, Torbicki A, Souza R, Ramírez A, Kurzyna M, Jardim C, Jerjes-Sánchez Díaz C, Teal SA, Hwang LJ, Pulido T; STRIDE-4 investigators. Sandoval J, et al. Pulm Pharmacol Ther. 2012 Feb;25(1):33-9. doi: 10.1016/j.pupt.2011.10.002. Epub 2011 Nov 2. Pulm Pharmacol Ther. 2012. PMID: 22079088 Clinical Trial.

5

Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.

Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ. Benza RL, et al. J Heart Lung Transplant. 2007 Jan;26(1):63-9. doi: 10.1016/j.healun.2006.10.019. J Heart Lung Transplant. 2007. PMID: 17234519 Clinical Trial.

6

Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension.

Widlitz AC, Barst RJ, Horn EM. Widlitz AC, et al. Expert Rev Cardiovasc Ther. 2005 Nov;3(6):985-91. doi: 10.1586/14779072.3.6.985. Expert Rev Cardiovasc Ther. 2005. PMID: 16292989 Review.

7

Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.

Rondelet B, Dewachter L, Kerbaul F, Dewachter C, Hubloue I, Fesler P, Franck S, Remmelink M, Brimioulle S, Naeije R. Rondelet B, et al. Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1118-23. doi: 10.1152/ajpheart.00418.2010. Epub 2010 Aug 6. Am J Physiol Heart Circ Physiol. 2010. PMID: 20693396 Free article.

8

Sitaxsentan sodium for pulmonary hypertension.

MacIntyre IM, Dhaun N, Goddard J, Webb DJ. MacIntyre IM, et al. Drugs Today (Barc). 2008 Aug;44(8):585-600. doi: 10.1358/dot.2008.44.8.1239808. Drugs Today (Barc). 2008. PMID: 18846270 Review.

9

Sitaxsentan (ICOS-Texas Biotechnology).

Wu-Wong JR. Wu-Wong JR. Curr Opin Investig Drugs. 2001 Apr;2(4):531-6. Curr Opin Investig Drugs. 2001. PMID: 11566012 Review.

10

A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.

Waxman AB. Waxman AB. Vasc Health Risk Manag. 2007;3(1):151-7. Vasc Health Risk Manag. 2007. PMID: 17583185 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

152 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Results by year